MINNEAPOLIS & CHICAGO--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced the results of a double-blind, randomized study, ISSUE-3, which found that patients who suffered from fainting due to neurocardiogenic syncope had fewer fainting occurrences when treated with a Medtronic pacemaker. The results, which found a statistically and clinically significant 57 percent relative reduction of fainting recurrence in patients at two years, were presented today in a late-breaking clinical trial session at the American College of Cardiology’s (ACC’s) 61st Annual Scientific Session in Chicago.
